Form 4: Emergent BioSolutions CFO Files Planned Tax-Related Stock Sale

Emergent BioSolutions' EVP and CFO, Richard S. Lindahl, filed a Form 4 reporting a pre-planned disposition of 4,995 common shares on October 15, 2025, to cover tax obligations related to restricted stock unit vesting under a Rule 10b5-1 plan.

Summary

• Richard S. Lindahl, Executive Vice President and Chief Financial Officer of Emergent BioSolutions Inc. (EBS), reported a planned transaction.
• The transaction, scheduled for October 15, 2025, involves the disposition of 4,995 shares of common stock.
• The shares were disposed of at a price of $9.6 per share.
• This disposition is specifically for paying taxes associated with the vesting and settlement of restricted stock units.
• The transaction is being made pursuant to a Rule 10b5-1 pre-arranged trading plan, as indicated by the checked box on the filing.
• Following this planned transaction, Lindahl will beneficially own 291,497 shares of common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine tax-related disposition of shares upon RSU vesting, indicating no discretionary buying or selling activity and thus has a neutral sentiment.

Future Outlook

The filing does not provide any forward-looking statements or guidance beyond the scheduled transaction date.

Industry Context

This type of insider transaction, involving the disposition of shares to cover tax liabilities upon the vesting of restricted stock units, is a common and routine event for executives across various industries. It reflects a standard component of executive compensation plans and is typically pre-arranged under Rule 10b5-1 plans to avoid accusations of trading on inside information.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary tax-related transaction by an executive, not indicative of a change in company fundamentals or executive sentiment.

Key Dates

Recommendation

The filing details a routine disposition of shares by a company executive to cover tax liabilities associated with the vesting of restricted stock units. This is a non-discretionary transaction, pre-arranged under a Rule 10b5-1 plan, and does not reflect a change in investment sentiment or company fundamentals. Therefore, a 'hold' recommendation is appropriate as it provides no new information to alter an existing investment thesis.

Keywords

Emergent BioSolutions, EBS, Richard S. Lindahl, CFO, Form 4, insider transaction, stock sale, tax withholding, restricted stock units, Rule 10b5-1